Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial. Issue 3 (15th November 2021)

• Record Type: Journal Article
• Authors: Hata, Shinnosuke; Nakajima, Hanako; Hashimoto, Yoshitaka; Miyoshi, Tomoki; Hosomi, Yukako; Okamura, Takuro; Majima, Saori; Nakanishi, Naoko; Senmaru, Takafumi; Osaka, Takafumi; Okada, Hiroshi; Ushigome, Emi; Hamaguchi, Masahide; Asano, Mai; Yamazaki, Masahiro; Fukui, Michiaki
• Is Part Of: Journal of diabetes investigation. Volume 13:Issue 3(2022)
• Page Start: 489
• Page End: 500
• Publication Date: 2021-11-15
• Subjects: Constipation -- Diarrhea -- Probiotics; Diabetes -- Periodicals; Diabetes -- Research -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1111/jdi.13698
• Languages: English
• ISSNs: 2040-1116

Abstract

ABSTRACT: Aims/Introduction: Metformin is associated with the risk of gastrointestinal complications, and probiotic Bifidobacterium bifidum G9‐1 (BBG9‐1) can improve the symptoms of diarrhea. This study aimed to clarify the effects of probiotic BBG9‐1 on the gastrointestinal symptoms of type 2 diabetes mellitus patients using metformin. Materials and methods: In this open‐label single‐arm exploratory study, 40 patients (mean age 64.0 ± 9.4 years) were given probiotic BBG9‐1 for 10 weeks. Changes in the gastrointestinal symptom rating scale total score, which was the primary end‐point, gastrointestinal symptom rating scale subscale scores, glycated hemoglobin levels and gut microbiota after the administration of probiotic BBG9‐1 were evaluated by the Student's t ‐test. Results: The gastrointestinal symptom rating scale total score significantly improved (from 2.02 ± 0.51 to 1.59 ± 0.43, change, −0.43 ± 0.49, P < 0.001). Furthermore, all gastrointestinal symptom rating scale subscale scores, including diarrhea (from 2.32 ± 1.14 to 1.89 ± 0.99, change, −0.42 ± 0.95, P = 0.007) and constipation (from 3.00 ± 1.16 to 2.20 ± 1.07, change, −0.80 ± 1.19, P < 0.001), scores also significantly improved. However, the glycated hemoglobin levels did not change (from 7.0 ± 0.7 to 7.0 ± 0.6%, change, 0.0 ± 0.4, P = 0.91). The relative abundance of the genus Sutterella decreased by the use of probiotic BBG9‐1 (from 0.011 ± 0.009 to 0.008 ± 0.006, change, −0.003 ± 0.006, P = 0.002). Conclusions: Type 2 diabetes mellitus patients treated with metformin showed significant improvement in all gastrointestinal symptom rating scores after using probiotic BBG9‐1 without changing the glucose control. This study showed the potential usefulness of probiotic BBG9‐1 for improving gastrointestinal symptoms, including constipation and diarrhea, in type 2 diabetes mellitus patients treated with metformin. Abstract : Probiotic Bifidobacterium bifidum G9‐1 (BBG9‐1) improved gastrointestinal symptoms, including diarrhea and constipation, without changing glucose control in type 2 diabetes mellitus patients treated with metformin. The relative abundance of the genus Sutterella decreased by the use of probiotic BBG9‐1.